Recognizing the Biological Barriers and Pathophysiological Characteristics of the Gastrointestinal Tract for the Design and Application of Nanotherapeutics

Overview

Journal Drug Deliv

Specialty Pharmacology

Date 2024 Oct 15

PMID 39404464

Authors

Shan Li

Tianyu Wu

Jingfeng Wu

Wensheng Chen

Dinglin Zhang

Affiliations

Soon will be listed here.

Abstract

The gastrointestinal tract (GIT) is an important and complex system by which humans to digest food and absorb nutrients. The GIT is vulnerable to diseases, which may led to discomfort or even death in humans. Therapeutics for GIT disease treatment face multiple biological barriers, which significantly decrease the efficacy of therapeutics. Recognizing the biological barriers and pathophysiological characteristics of GIT may be helpful to design innovative therapeutics. Nanotherapeutics, which have special targeting and controlled therapeutic release profiles, have been widely used for the treatment of GIT diseases. Herein, we provide a comprehensive review of the biological barrier and pathophysiological characteristics of GIT, which may aid in the design of promising nanotherapeutics for GIT disease treatment. Furthermore, several typical diseases of the upper and lower digestive tracts, such as infection and inflammatory bowel disease, were selected to investigate the application of nanotherapeutics for GIT disease treatment.

References

Vafaei S, Esmaeili M, Amini M, Atyabi F, Ostad S, Dinarvand R . Self assembled hyaluronic acid nanoparticles as a potential carrier for targeting the inflamed intestinal mucosa. Carbohydr Polym. 2016; 144:371-81. DOI: 10.1016/j.carbpol.2016.01.026. View

Birchenough G, Johansson M, Gustafsson J, Bergstrom J, Hansson G . New developments in goblet cell mucus secretion and function. Mucosal Immunol. 2015; 8(4):712-9. PMC: 4631840. DOI: 10.1038/mi.2015.32. View

Dou Y, Li C, Li L, Guo J, Zhang J . Bioresponsive drug delivery systems for the treatment of inflammatory diseases. J Control Release. 2020; 327:641-666. PMC: 7476894. DOI: 10.1016/j.jconrel.2020.09.008. View

Colas C, Masuda M, Sugio K, Miyauchi S, Hu Y, Smith D . Chemical Modulation of the Human Oligopeptide Transporter 1, hPepT1. Mol Pharm. 2017; 14(12):4685-4693. PMC: 5826771. DOI: 10.1021/acs.molpharmaceut.7b00775. View

Jones N, Ray B, Ranjit K, Manna A . Antibacterial activity of ZnO nanoparticle suspensions on a broad spectrum of microorganisms. FEMS Microbiol Lett. 2007; 279(1):71-6. DOI: 10.1111/j.1574-6968.2007.01012.x. View

Cone R . Barrier properties of mucus. Adv Drug Deliv Rev. 2009; 61(2):75-85. DOI: 10.1016/j.addr.2008.09.008. View

Gong W, Yu J, Zheng T, Liu P, Zhao F, Liu J . CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease. Clin Transl Med. 2021; 11(2):e339. PMC: 7888545. DOI: 10.1002/ctm2.339. View

Adibi S . The oligopeptide transporter (Pept-1) in human intestine: biology and function. Gastroenterology. 1997; 113(1):332-40. DOI: 10.1016/s0016-5085(97)70112-4. View

De Falco M, Lucariello A, Iaquinto S, Esposito V, Guerra G, De Luca A . Molecular Mechanisms of Helicobacter pylori Pathogenesis. J Cell Physiol. 2015; 230(8):1702-7. DOI: 10.1002/jcp.24933. View

10.

Zhang Y, Ma R, You C, Leng X, Wang D, Deng S . Hyaluronic acid modified oral drug delivery system with mucoadhesiveness and macrophage-targeting for colitis treatment. Carbohydr Polym. 2023; 313:120884. DOI: 10.1016/j.carbpol.2023.120884. View

11.

Ferguson A . Intraepithelial lymphocytes of the small intestine. Gut. 1977; 18(11):921-37. PMC: 1411743. DOI: 10.1136/gut.18.11.921. View

12.

Xiao B, Laroui H, Viennois E, Ayyadurai S, Charania M, Zhang Y . Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology. 2014; 146(5):1289-300.e1-19. PMC: 3992175. DOI: 10.1053/j.gastro.2014.01.056. View

13.

Kuo C, Lu C, Yang Y, Chin C, Weng B, Liu C . Does long-term use of silver nanoparticles have persistent inhibitory effect on H. pylori based on Mongolian gerbil's model?. Biomed Res Int. 2014; 2014:461034. PMC: 4016839. DOI: 10.1155/2014/461034. View

14.

Maisel K, Ensign L, Reddy M, Cone R, Hanes J . Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J Control Release. 2014; 197:48-57. PMC: 4272879. DOI: 10.1016/j.jconrel.2014.10.026. View

15.

Li S, Wu T, Wu J, Zhou J, Yang H, Chen L . Cyclosporine A-Encapsulated pH/ROS Dual-Responsive Nanoformulations for the Targeted Treatment of Colitis in Mice. ACS Biomater Sci Eng. 2023; 9(10):5737-5746. DOI: 10.1021/acsbiomaterials.3c01191. View

16.

Laroui H, Wilson D, Dalmasso G, Salaita K, Murthy N, Sitaraman S . Nanomedicine in GI. Am J Physiol Gastrointest Liver Physiol. 2010; 300(3):G371-83. PMC: 3064120. DOI: 10.1152/ajpgi.00466.2010. View

17.

Zhang X, Guan X, Tang Y, Sun J, Wang X, Wang W . Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis. Eur J Nutr. 2021; 60(5):2855-2875. DOI: 10.1007/s00394-021-02503-5. View

18.

Ifrim Chen F, Antochi A, Barbilian A . Acupuncture and the retrospect of its modern research. Rom J Morphol Embryol. 2019; 60(2):411-418. View

19.

Ma Y, Gao W, Zhang Y, Yang M, Yan X, Zhang Y . Biomimetic MOF Nanoparticles Delivery of C-Dot Nanozyme and CRISPR/Cas9 System for Site-Specific Treatment of Ulcerative Colitis. ACS Appl Mater Interfaces. 2022; 14(5):6358-6369. DOI: 10.1021/acsami.1c21700. View

20.

Jubeh T, Barenholz Y, Rubinstein A . Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm Res. 2004; 21(3):447-53. DOI: 10.1023/B:PHAM.0000019298.29561.cd. View